Hybrid nanoparticle-immune cell conjugates for augmented anticancer efficacy

Area of Science:

• Immunology
• Biotechnology
• Materials Science

Background:

• Cell-based therapies, including CAR-T and CAR-NK cells, are vital in cancer immunotherapy.
• Cell surface engineering with nanoparticles offers a complementary strategy to modulate immune cell functions.

Purpose of the Study:

• To review key aspects of nanoparticle-cell conjugate (NCC) development for cancer immunotherapy.
• To explore nanoparticle design, conjugation strategies, limitations, and the role of AI in NCCs.

Main Methods:

• Discussion of various cell surface engineering techniques: hydrophobic insertion, covalent conjugation, glycoengineering, orthogonal chemistry, and host-guest interactions.
• Analysis of nanoparticle design criteria and NCC strategies for programmable interactions and controlled release.
• Examination of limitations in current direct conjugation methods.

Main Results:

• Nanoparticle-cell conjugates enable programmable interactions, controlled release, and enhanced tumor targeting.
• Current conjugation methods face challenges with cell viability and ligand-receptor specificity.
• Artificial intelligence (AI) shows potential in designing advanced cell-based therapies.

Conclusions:

• Nanoparticle-cell conjugates represent a modular and promising alternative to genetic engineering in next-generation cancer immunotherapy.
• NCCs expand the therapeutic toolkit for developing advanced immunotherapies.